Walleye Capital’s Contineum Therapeutics CTNM Stock Holding History
Bought
Maintained
Sold
Other funds holding CTNM
Walleye Capital's CTNM Position: Q3 2026 in Review
Walleye Capital opened a new position in Contineum Therapeutics (CTNM) in Q3 2026: 18,201 shares worth $244K. The stake represents ﹤0.01% of the portfolio and ranks #4668 among its holdings. This is a return to the name: Walleye Capital previously reported a position in CTNM as recently as Q2 2024.
Walleye Capital first reported a position in CTNM in Q2 2024 and has held it in 2 quarters since. The position peaked at $778K in Q2 2024. 118 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.
- Walleye Capital held 18,201 shares of Contineum Therapeutics worth $244K as of Q3 2026.
- Contineum Therapeutics was a new Walleye Capital position in Q3 2026.
- Contineum Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4668 holding.
- Walleye Capital first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 2 quarters since.
- Walleye Capital's Contineum Therapeutics position peaked at $778K in Q2 2024.
- 118 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.